^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + Imfinzi (durvalumab) (PD-L1 inhibitor) + Recentin (cediranib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses
Published date:
07/25/2019
Excerpt:
The RP2D is cediranib, 20 mg (5 days on/2 days off) with full doses of durvalumab and olaparib. Tumoral PD-L1 expression correlated with clinical benefit but cytokines and peripheral immune subsets did not.
DOI:
10.1186/s40425-019-0680-3
Trial ID:
